Telemus Capital LLC Raises Position in Danaher Co. (NYSE:DHR)

Telemus Capital LLC lifted its position in Danaher Co. (NYSE:DHR) by 15.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,480 shares of the conglomerate’s stock after acquiring an additional 2,085 shares during the period. Telemus Capital LLC’s holdings in Danaher were worth $3,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Banco Santander S.A. acquired a new position in shares of Danaher in the 3rd quarter valued at $683,000. First Citizens Bank & Trust Co. grew its position in Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the period. Allspring Global Investments Holdings LLC grew its position in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after purchasing an additional 96,395 shares during the period. Parkside Financial Bank & Trust grew its position in Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after purchasing an additional 142 shares during the period. Finally, Keybank National Association OH grew its position in Danaher by 0.5% during the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after purchasing an additional 2,567 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DHR has been the topic of several analyst reports. Barclays increased their price target on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, KeyCorp raised their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Danaher Trading Up 0.2 %

DHR opened at $236.08 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The company’s 50 day simple moving average is $248.72 and its two-hundred day simple moving average is $230.39. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The firm has a market capitalization of $174.83 billion, a price-to-earnings ratio of 36.95, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.87 EPS. Analysts expect that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is presently 16.90%.

Insider Activity at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,957 shares of company stock worth $8,265,802. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.